A positive group B streptococcus is indicative of the presence of a group B streptococcus infection. No specific treatment is required in the non-pregnant state, and medication is usually recommended prior to delivery for pregnant women with positive group B streptococci in the absence of clinical symptoms.
Group B streptococcal infections are the most common pathogens of the female reproductive system, but in the nonpregnant state they are asymptomatic and usually do not require treatment.
However, in women who are pregnant and in labor, group B streptococci can lead to adverse pregnancies such as late miscarriage, fetal growth restriction, premature rupture of membranes, and preterm labor, as well as reversal of group B streptococcal infection in the fetus.
In clinically group B streptococcus-positive pregnant women, the drug of choice for treatment is usually penicillin in order to avoid adverse pregnancy and maternal and fetal complications as much as possible. However, treatment regimens vary for different disease types. Antibiotics such as erythromycin and cephalosporins may be used in those who are allergic to penicillin. Typically, in pregnant women who are positive for group B streptococcus in pregnancy without clinical symptoms, aggressive treatment before delivery is usually recommended.
Therefore, it is necessary to screen all pregnant women for group B streptococcal infections during labor and the perinatal period, and early intervention will play a positive role in improving the prognosis for mother and child.